Astellas Entered into a Research Collaboration and License Agreement with PeptiDream to Discover Novel Targeted Protein Degraders
Shots:
- PeptiDream will receive $21M up front & is also eligible for ~$145M per target in discovery, development, and commercial sales milestones along with royalty on net sales of any products that emerge from the collaboration
- Astellas will get an option to select up to three additional targets & will lead the development and commercialization of products.
- The collaboration will combine PeptiDream's PDPS (Peptide Discovery Platform System) technology with Astellas' drug discovery capabilities to discover multiple next-generation protein degraders targeting diverse targets. The collaboration also enables an expansion of Astellas’ portfolio and the development of new therapeutics
Ref: Businesswire | Image: Astellas
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
